newsfilter
← Latest News
GlobeNewswire·

UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological Disorders

Filing seeks to extend EL-22 myostatin-engineered probiotic platform into pharmaceutical applications for muscle preservation in patients on GLP-1 receptor agonists and across multiple muscle-wasting indications NEWPORT